These conclusions remained valid if the patients with brain tumors, lymphoma/leukemia, thymoma, and NF were excluded, with P values of < 0.01 for association between MET alterations and TP53 or PTEN alterations, bone metastases, and increased number of metastases. Here, MET is linked to leukemia.